Abstract

T Troosters has received grants from Innovative Medicines Initiative Joint Undertaking and speaker fees from Boehringer Ingelheim and GlaxoSmithKline.

J Bourbeau has received grants from the Canadian Institute of Health Research R&D collaborative programme (AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Nycomed, Novartis), Canadian Respiratory Research Network, Respiratory Health Network of the FRQS and Research Institute of the MUHC, and an educational grant from GlaxoSmithKline.

F Maltais has received grants from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Nycomed and Pfizer, personal fees from Boehringer Ingelheim, GlaxoSmithKline and Novartis, and other financial support from GlaxoSmithKline.

N Leidy is employed by Evidera, a health-care research firm that provides consulting and other research services to pharmaceutical and other organisations including the study sponsor.

D Erzen, D De Sousa, L Korducki and A Hamilton are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.

KL Lavoie reports personal fees from Boehringer Ingelheim for personnel training as well as a grant from AbbVie and personal fees from Bayer, Janssen, Novarits, AbbVie, Mundipharma and Almirall.

W Janssens has no conflict of interest to report.